Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily

Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicate that approximately 20–25% of patients are prescribed a higher dose than the maximum recommended dosage of nine breaths per treatment session (bps) (54 μg), four times a day (QI...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Shelley, Mandras, Stacy, Restrepo-Jaramillo, Ricardo, Shen, Eric, Broderick, Meredith, Rao, Youlan, Lee, Dasom, Nelsen, Andrew C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558813/
https://www.ncbi.nlm.nih.gov/pubmed/34733493
http://dx.doi.org/10.1177/20458940211052228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558813/
https://www.ncbi.nlm.nih.gov/pubmed/34733493
http://dx.doi.org/10.1177/20458940211052228

Ejemplares similares